Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(11 sites)
United States
Highlands Oncology Group, Rogers, Arkansas Yale University Cancer Center, New Haven, Connecticut Massachusetts General Hospital, Boston, Massachusetts MD Anderson Cancer Center, Houston, Texas START San Antonio, San Antonio, Texas Australia
Macquarie University Hospital, Macquarie Park, New South Wales Scientia Clinical Research, Randwick, New South Wales Southern Oncology Clinical Research Unit, Bedford Park, South Australia Peninsula and South Eastern Haematology and Oncology Group (PSEHOG), Frankston, Victoria Cabrini Hospital, Malvern, Victoria Linear Clinical Research, Nedlands, Western Australia